Yonsa (Abiraterone Acet,Submicronized) Patent Expiration, LOE Window & CMS Spending

Yonsa (Abiraterone Acet,Submicronized) by Sun Pharmaceutical: FDA Orange Book LOE 2034-05-20, 12 AB generics, $15.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSun Pharmaceutical
FDA Application & PathwayN210308 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-05-20
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$15.9M
2024 Medicare Part D Spend$15.5M
2024 Medicaid Spend$403K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel